摘要
目的：探讨阿奇霉素序贯疗法联合双黄连口服液对支原体肺炎患儿T淋巴细胞亚群及血清白细胞介素（TL-6）、肿瘤坏死因子（TNF-α）、超敏C-反应蛋白（hs-CRP）水平的影响。方法：研究对象选自我院2015年3月-2016年12月收治的172例支原体肺炎患儿，采取随机数字表将其分成两组，每组86例。两组患儿均给予阿奇霉素序贯疗法治疗，观察组联合给予双黄连口服液，对比两组临床疗效、治疗前后T淋巴细胞亚群及血清IL-6、TNF-α、hs—CRP水平的变化情况。结果：观察组的总有效率为96．51％，较对照组（88.37％）明显上升（P〈0．05）。两组患儿治疗后T淋巴细胞亚群CD3^＋、CD4^＋比例、CD4^＋／CD8^＋均较治疗前显著升高（P〈0．01），CD8^＋,血清IL-6、TNF-α、hs-CRP水平较治疗前显著下降，且观察组患儿以上指标的改善程度较对照组更明显（P〈0．01）。两组患儿不良反应的发生率对比差异无统计学意义（P〉0．05）。结论：阿奇霉素序贯疗法联合双黄连口服液治疗小儿支原体肺炎可有效改善患儿的免疫功能，减轻炎症反应，疗效确切，且安全性高。
Objective： To explore the effect of sequential therapy with azithromycin combined with shuanghuanglian oral liquid on the T lymphocyte subsets, serum interleukin-6 （IL-6）, tumor necrosis factor （TNF）-α and high sensitivity C-reactive protein （hs-CRP） levels of children with mycoplasma pneumonia. Methods： 172 cases of children with mycoplasma pneumonia in our hospital from March 2015 to December 2016 were selected and randomly divided into two groups with 86 cases in each group. Sequential therapy with azithromycin were given to both groups and shuanghuanglian oral liquid was given to the observation group additionally. The clinical effect, T lymphocyte subsets, serum IL-6, TNF-α and hs-CRP levels before and after treatment were compared between two groups. Results： The total effective rate of observation group was 96.51%, which was significantly higher than that of the control group （88.37%） （P〈0.05）. The T lymphocyte subsets CD3^＋, CD4^＋ ratio, CD4^＋/CD8^＋ of both groups of children after treatment were significantly higher than those before treatment （P〈0.01）, the CD81, serum IL-6, TNF-α and hs-CRP levels were significantly lower than those before treatment, and the improvement of the indicators mentioned above in the observation group were more obvious than those of the control group （P〈0.01）. No significant difference was found in the incidence of adverse reactions between two groupsP〉0.05）. Conclusion： Azithromycin sequential therapy combined with Shuanghuanglian oral liquid could effectively improve the immune function, reduce inflammatory response with high safety for the children with mycoplasma pneumonia.
出处
《现代生物医学进展》
CAS
2017年第26期5169-5172,共4页
Progress in Modern Biomedicine
基金
陕西省自然科学基金项目（26H9675）
关键词
阿奇霉素
序贯疗法
双黄连口服液
支原体肺炎
T淋巴细胞亚群
炎性因子
Azithromycin
Sequential therapy
Shuanghuanglian oral liquid
Mycoplasma pneumonia
T lymphocyte subsets
Inflammatory factor
